Custirsen (OGX-011): Clusterin Inhibitor in Metastatic Prostate Cancer
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Custirsen (OGX-011): Clusterin Inhibitor in Metastatic Prostate Cancer
Authors
Keywords
Custirsen, Clusterin, Prostate cancer, Antisense oligonucleotides, Resistance
Journal
Current Oncology Reports
Volume 15, Issue 2, Pages 113-118
Publisher
Springer Nature
Online
2012-12-24
DOI
10.1007/s11912-012-0285-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- International Variation in Prostate Cancer Incidence and Mortality Rates
- (2012) Melissa M. Center et al. EUROPEAN UROLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c
- (2011) F. Saad et al. CLINICAL CANCER RESEARCH
- Chemotherapy-Based Treatment for Castration-Resistant Prostate Cancer
- (2011) Bostjan Seruga et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global Patterns of Cancer Incidence and Mortality Rates and Trends
- (2010) A. Jemal et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer
- (2010) A. Zoubeidi et al. CLINICAL CANCER RESEARCH
- Castration-Resistant Prostate Cancer
- (2010) Giuseppe Di Lorenzo et al. DRUGS
- Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2010) Kim N. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- The clusterin paradigm in prostate and breast carcinogenesis
- (2009) Federica Rizzi et al. ENDOCRINE-RELATED CANCER
- Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells
- (2009) Federica Rizzi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread
- (2009) S Bettuzzi et al. ONCOGENE
- Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy
- (2008) Richard D. Sowery et al. BJU INTERNATIONAL
- A Phase I Study of OGX-011, a 2'-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer
- (2008) K. N. Chi et al. CLINICAL CANCER RESEARCH
- ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel
- (2008) T. M. Sissung et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now